ArticleBritish journal of cancer2012

The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer.

H M Coley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.